Neogen CLO granted shares and stock options

NEOGEN CORP Chief Legal Officer Stacey Jennifer Evans reported equity awards of common stock and stock options.

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

NEOGEN CORP Chief Legal Officer Stacey Jennifer Evans reported equity awards of common stock and stock options. She received 39,349 shares of Common Stock on May 1, 2026, valued at $9.53 per share, and now holds that amount directly.

On the same date she was granted 89,520 options to buy Common Stock at an exercise price of $9.53 per share, expiring on May 1, 2036. According to the footnote, these options and related RSUs vest in equal annual installments over three years, making this a multi-year compensation grant rather than an open-market trade.

Insider Trade Summary

Grant/Award: 128,869 shares

Grant/Award 2 txns

Insider Stacey Jennifer Evans

Role Chief Legal Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock (Right to Buy)	89,520	$0.00	$0.00
Grant/Award	Common Stock	39,349	$9.53	$375K

Holdings After Transaction: Common Stock (Right to Buy) — 89,520 contracts (Direct); Common Stock — 39,349 shares (Direct)

Footnotes (1)

F1. Options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants

Key Figures

Common stock award: 39,349 shares Grant value per share: $9.53 per share Options granted: 89,520 options +3 more

6 metrics

Common stock award 39,349 shares Direct Common Stock held after May 1, 2026 grant

Grant value per share $9.53 per share Value used for 39,349-share Common Stock award

Options granted 89,520 options Common Stock (Right to Buy) granted May 1, 2026

Option exercise price $9.53 per share Conversion or exercise price for 89,520 options

Option expiration date May 1, 2036 Expiration date of the 89,520 stock options

Vesting schedule 3 annual installments Options and RSUs vest over three years from grant date

Key Terms

Common Stock (Right to Buy), Grant, award, or other acquisition, conversion or exercise price, Options and RSUs vest

4 terms

Common Stock (Right to Buy) financial

"security_title": "Common Stock (Right to Buy)""

Grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

conversion or exercise price financial

"conversion_or_exercise_price": "9.5300""

Options and RSUs vest financial

"Options and RSUs vest in equal annual installments"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did NEOG (Neogen) report for Stacey Jennifer Evans?

Neogen reported that Chief Legal Officer Stacey Jennifer Evans received equity compensation on May 1, 2026. She was awarded 39,349 shares of Common Stock and 89,520 options, all classified as grants or awards rather than open-market purchases or sales.

How many Neogen (NEOG) shares did the Chief Legal Officer receive in this Form 4?

The Chief Legal Officer received 39,349 shares of Neogen Common Stock as a direct equity award. This grant is reported at a value of $9.53 per share and represents her total direct share holdings following the reported transaction.

What stock options were granted to the Neogen (NEOG) Chief Legal Officer?

Stacey Jennifer Evans was granted 89,520 options labeled as “Common Stock (Right to Buy)” with an exercise price of $9.53 per share. These options give her the right to purchase an equal number of Neogen common shares before their stated expiration date.

When do the Neogen (NEOG) options granted to the CLO expire?

The options granted to the Chief Legal Officer on May 1, 2026, expire on May 1, 2036. This 10-year term is typical for employee stock options, allowing a long window to exercise if vesting conditions and other plan requirements are satisfied.

How do the Neogen (NEOG) options and RSUs for the CLO vest?

According to the footnote, the options and related RSUs vest in equal annual installments on each of the first three anniversaries of the grant dates. This creates a three-year vesting schedule tied to continued service or other plan conditions.

Did the Neogen (NEOG) Chief Legal Officer buy or sell shares on the open market?

The filing shows only grant or award acquisitions, coded as “A,” not open-market trades. The transactions are equity compensation awards of shares and options, rather than discretionary buying or selling of Neogen stock in the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 05/04/2026 - 04:52 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stacey Jennifer Evans

(Last)

(First)

(Middle)

620 LESHER PLACE

(Street)

LANSING

MICHIGAN

48912

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NEOGEN CORP [ NEOG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/01/2026		A		39,349⁽¹⁾	A	$9.53	39,349	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock (Right to Buy)	$9.53	05/01/2026		A		89,520		⁽¹⁾	05/01/2036	Common Stock	89,520	$0	89,520	D

Explanation of Responses:

1. Options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants

	Christopher Sefcheck (attorney in fact)	05/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR